IL-6 blockades with tocilizumab did not improve short-term survival in advanced pancreatic cancer but showed potential ...

ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, ...

Olawaiye noted that the combination is a "well-tolerated regimen and we believe it should be a new standard for platinum-resistant ovarian cancer therapy." Results from the study ...

The oncogene AEG-1 shows promise as a target for managing chemotherapy-induced peripheral neuropathy, according to a recently published study.

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

THP combines one chemotherapy drug (a taxane ... THP (4 cycles of trastuzumab and pertuzumab (HP)) with weekly paclitaxel (12 weeks) or docetaxel (q3w x 4), followed by surgery.

The phase III trial, which enrolled 2233 patients, compared two dose-dense chemotherapy regimens: Weekly nab-paclitaxel (125 mg/m 2 for eight cycles) vs biweekly solvent-based paclitaxel (175 mg/m ...

In the trial, 207 patients HR+/HER2+ EBC stages 1 to 3 were allocated to 12 weeks of neoadjuvant standard endocrine therapy (100 patients) versus paclitaxel chemotherapy (Pac) (107 patients) weekly ...

They split this group into two arms, one of which received six weekly doses of carboplatin and paclitaxel chemotherapy before receiving up to 6 weeks of chemotherapy drug cisplatin and radiation ...